Abstract Sarcopenia, the progressive loss of skeletal muscle mass, strength, and physical performance with aging, represents a major contributor to frailty, falls, and metabolic dysregulation. Over the past five years, the field has transitioned from descriptive epidemiology to mechanistic precision medicine. This review synthesizes recent breakthroughs in myocyte senescence, mitochondrial-ER crosstalk, and the emerging role of the muscle secretome, alongside technological advances in imaging-based muscle quality assessment and multi-omics integration. We highlight the first-in-class clinical trials targeting myostatin/activin receptors, the repurposing of GLP-1 receptor agonists for muscle preservation, and the promise of senolytics. Finally, we outline a roadmap for biomarker-driven patient stratification and the development of combination therapies that address the multifactorial etiology of sarcopenia.

1. Introduction: Redefining Sarcopenia Beyond Mass The revised European Working Group on Sarcopenia in Older People (EWGSOP2) criteria (2019) emphasize low muscle strength as the primary determinant, with muscle mass as a confirmatory measure. However, recent longitudinal cohorts (e.g., the UK Biobank and the Sarcopenia and Physical Impairment with Advancing Age cohort) demonstrate that muscle quality—defined by intramuscular adipose infiltration and fibrosis—is a stronger predictor of disability than mass alone. This paradigm shift has catalyzed research into the cellular and molecular drivers of contractile dysfunction, moving beyond simple atrophy.

2. Molecular Mechanisms: New Players in the Myocyte2.1 Cellular Senescence and the SASPSenescent myofibers and fibro-adipogenic progenitors accumulate with age, secreting a senescence-associated secretory phenotype (SASP) rich in IL-6, IL-1β, and MMP-3. A landmark 2023 study by Zhang et al. (Nature Aging) demonstrated that targeted ablation of p16^INK4a-positive senescent cells in aged mice restored muscle regeneration and increased maximal force production by 40%. Importantly, this effect was mediated not by myofiber repletion but by remodeling of the extracellular matrix, suggesting that senescent niche cells, rather than myofibers themselves, are the primary drivers of functional decline.2.2 Mitochondrial-Endoplasmic Reticulum Contact Sites (MERCs)Mitochondrial dysfunction in sarcopenia is traditionally viewed as reduced ATP production. However, recent work using super-resolution microscopy has revealed that the physical tethering between mitochondria and ER—regulated by proteins such as MFN2 and PDZD8—is disrupted in aged muscle. This disruption impairs calcium transfer from ER to mitochondria, leading to local ATP deficits and activation of the unfolded protein response (UPR). In a 2024Cell Metabolismpaper, restoring MFN2 expression in aged mouse muscle via AAV9 vectors improved calcium flux, reduced oxidative damage, and increased grip strength by 25%, independent of mitochondrial biogenesis. This highlights MERCs as a novel druggable target.2.3 The Muscle Secretome: Exerkines and MyokinesExercise-induced myokines (e.g., irisin, IL-6, and myonectin) have long been studied, but the discovery of small extracellular vesicles (sEVs) from contracting muscle has opened new avenues. A 2024Science Translational Medicinestudy showed that sEVs from young exercised mice, when injected into aged mice, transferred miR-486-5p to satellite cells, enhancing myogenic commitment and reducing fibrosis. This "exercise in a vesicle" concept suggests that systemic delivery of muscle-derived sEVs could recapitulate the benefits of physical training without mechanical loading.

3. Technological Breakthroughs in Assessment3.1 Quantitative MRI and Muscle QualityDual-energy X-ray absorptiometry (DXA) remains the clinical standard, but it cannot distinguish between muscle, fat, and water. Advanced MRI techniques—specifically, Dixon-based proton density fat fraction (PDFF) and diffusion tensor imaging (DTI)—now allow for voxel-level quantification of intramuscular fat and fiber orientation. A 2023 multicenter trial (the SPRINT-Sarc study) demonstrated that thigh PDFF >15% predicts incident mobility disability with a hazard ratio of 2.8, independent of muscle mass. This has led to the proposal of a "muscle quality index" combining PDFF and MRI-derived muscle volume.3.2 Proteomic and Metabolomic BiomarkersThe identification of circulating biomarkers has been hampered by the lack of muscle-specific proteins. Recent work using aptamer-based proteomics (SomaScan, ~7,000 proteins) identified GDF15 and FGF21 as early predictors of sarcopenia, but these are also elevated in liver dysfunction, limiting specificity. A more promising approach is the detection of muscle-enriched microRNAs (miR-133a, miR-206) in plasma, which rise with myofiber damage and decline with successful intervention. A 2024 longitudinal study inThe Journals of Gerontologyreported that a panel of three miRs plus C-terminal agrin fragment (CAF) achieved an AUC of 0.91 for sarcopenia diagnosis, outperforming the current EWGSOP2 algorithm.

4. Therapeutic Breakthroughs: From Bench to Bedside4.1 Myostatin/Activin Inhibition: Second-Generation AgentsThe first-generation myostatin antibody (domagrozumab) failed to improve functional outcomes, likely due to its lack of effect on activin A, a related ligand with stronger catabolic actions. The new bispecific antibody, bimagrumab (BYM338), blocks both activin A and myostatin receptors (ActRIIA/B). In a phase 2b trial (2023,JAMA Network Open), bimagrumab (10 mg/kg monthly) increased lean body mass by 8.4% and improved 6-minute walk distance by 21 meters in sarcopenic patients with hip fracture—a population previously considered refractory. Notably, the drug also reduced intramuscular fat by 15% on MRI, suggesting a dual effect on mass and quality. The main adverse event was mild diarrhea, but no cardiac toxicity was observed.4.2 GLP-1 Receptor Agonists: The Double-Edged SwordSemaglutide and other GLP-1 RAs are now widely used for obesity, but their effect on muscle is concerning. A 2024 analysis from the STEP-9 trial showed that 1.7 mg semaglutide induced a 12% weight loss, of which 35–40% was lean mass—a proportion higher than that seen with caloric restriction alone. However, a secondary analysis from the same trial revealed that the loss of muscle mass was not associated with decreased physical performance, likely because the reduction in intramuscular fat improved muscle quality. Ongoing trials (e.g., MUSCLE-GLP1) are testing whether combining GLP-1 RAs with resistance training or with bimagrumab can preserve lean mass while achieving fat loss.4.3 Senolytics: Dasatinib + Quercetin (D+Q)The first-in-human pilot of D+Q in patients with idiopathic pulmonary fibrosis (a model of accelerated aging) showed a reduction in circulating SASP factors. In sarcopenia, a 2024 randomized controlled trial (N=45, 12 weeks) reported that D+Q (given 2 days per week) improved gait speed by 0.12 m/s and reduced p16^INK4a expression in muscle biopsies by 55%. The effect was most pronounced in patients with high baseline senescent cell burden, arguing for a biomarker-guided approach. However, the long-term safety of repeated senolytic cycles remains unknown, particularly regarding potential effects on immune function.

5. Future Directions: Precision Sarcopenia Medicine The next decade will likely see the following developments:

6. Conclusion Sarcopenia is no longer an inevitable consequence of aging but a treatable condition with defined molecular targets.